Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES135 in Spinal Cord Injury
NCT03229031Phase 3Suspended
- Sponsor
- Eusol Biotech Co., Ltd.
- Start
- Mar 2018
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ES135 in spinal cord injury (SCI), sponsored by Eusol Biotech Co., Ltd.. Started Mar 2018; status: suspended.
02
Drugs
ES135
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT03229031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229031.